New study checks if maribavir works safely for transplant patients with stubborn CMV

NCT ID NCT06213974

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 10 adults and children (12 years and older) in Argentina who have a CMV infection after an organ transplant that did not get better with standard treatments. Researchers will track how well maribavir works and what side effects occur during routine care. The goal is to see if the drug is safe and effective in real-world use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • IC Projects

    RECRUITING

    City of Buenos Aires, C11119ACN, Argentina

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact